Literature DB >> 28780040

Long-term direct visualization of passively transferred fluorophore-conjugated antibodies.

Jeffrey R Schneider1, Ann M Carias1, Arangaserry R Bastian2, Gianguido C Cianci1, Patrick F Kiser3, Ronald S Veazey4, Thomas J Hope5.   

Abstract

The use of therapeutic antibodies, delivered by intravenous (IV) instillation, is a rapidly expanding area of biomedical treatment for a variety of conditions. However, little is known about how the antibodies are anatomically distributed following infusion and the underlying mechanism mediating therapeutic antibody distribution to specific anatomical sites remains to be elucidated. Current efforts utilize low resolution and sensitivity methods such as ELISA and indirect labeling imaging techniques, which often leads to high background and difficulty in assessing biodistribution. Here, using the in vivo non-human primate model, we demonstrate that it is possible to utilize the fluorophores Cy5 and Cy3 directly conjugated to antibodies for direct visualization and quantification of passively transferred antibodies in plasma, tissue, and in mucosal secretions. Antibodies were formulated with 1-2 fluorophores per antibody to minimally influence antibody function. Fluorophore conjugated Gamunex-C (pooled human IgG) were tested for binding to protein A, via surface plasmon resonance, and showed similar levels of binding when compared to unlabeled Gamunex-C. In order to assess the effect fluorophore labeling has on turnover and localization, rhesus macaques were IV infused with either labeled or unlabeled Gamunex-C. Plasma, vaginal Weck-Cel fluid, cervicovaginal mucus, and vaginal/rectal tissue biopsies were collected up to 8weeks. Similar turnover and biodistribution was observed between labeled and unlabeled antibodies, showing that the labeling process did not have an obvious deleterious effect on localization or turnover. Cy5 and Cy3 labeled antibodies were readily detected in the same pattern regardless of fluorophore. Tissue distribution was measured in macaque vaginal and rectal biopsies. The labeled antibody in macaque biopsies was found to have similar biodistribution pattern to endogenous antibodies in macaque and human tissues. In the vaginal and rectal mucosa, endogenous and infused antibodies were found primarily within the lamina propria. In the mucosal squamous epithelium of the vaginal vault, significant antibody was also observed in a striated pattern in the superficial, nonviable, stratum corneum. Endogenous antibody distribution in both human and macaque squamous tissues exhibited a similar pattern as seen with the labeled and unlabeled antibodies. This proof-of-principle study reveals that the labeled antibody is stable and physiologically similar relative to endogenous antibody setting the stage for future work to better understand the mechanisms of how antibodies reach unique anatomical sites. Direct visualization of fluorophore-conjugated antibodies following passive infusion can be utilized to assess the kinetics of biodistribution of infused antibodies and may be a useful approach to monitor and predict efficacy of therapeutic antibodies.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28780040      PMCID: PMC5603196          DOI: 10.1016/j.jim.2017.07.009

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  12 in total

1.  The impact of glycosylation on monoclonal antibody conformation and stability.

Authors:  Kai Zheng; Christopher Bantog; Robert Bayer
Journal:  MAbs       Date:  2011-11-01       Impact factor: 5.857

2.  Preventing intense false positive and negative reactions attributed to the principle of ELISA to re-investigate antibody studies in autoimmune diseases.

Authors:  Kuniaki Terato; Christopher T Do; Dawn Cutler; Takaki Waritani; Hiroshi Shionoya
Journal:  J Immunol Methods       Date:  2014-03-27       Impact factor: 2.303

3.  Non-specific binding in solid phase immunoassays for autoantibodies correlates with inflammation markers.

Authors:  Esin Güven; Karen Duus; Magnus Christian Lydolph; Charlotte Sværke Jørgensen; Inga Laursen; Gunnar Houen
Journal:  J Immunol Methods       Date:  2013-11-25       Impact factor: 2.303

4.  Anomalous fluorescence enhancement of Cy3 and cy3.5 versus anomalous fluorescence loss of Cy5 and Cy7 upon covalent linking to IgG and noncovalent binding to avidin.

Authors:  H J Gruber; C D Hahn; G Kada; C K Riener; G S Harms; W Ahrer; T G Dax; H G Knaus
Journal:  Bioconjug Chem       Date:  2000 Sep-Oct       Impact factor: 4.774

Review 5.  The therapeutic monoclonal antibody market.

Authors:  Dawn M Ecker; Susan Dana Jones; Howard L Levine
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 6.  Proper application of antibodies for immunohistochemical detection: antibody crimes and how to prevent them.

Authors:  Richard Ivell; Katja Teerds; Gloria E Hoffman
Journal:  Endocrinology       Date:  2014-01-15       Impact factor: 4.736

7.  The quantitation of nonspecific staining as a guide for improvement of fluorescent antibody conjugates.

Authors:  B Pittman; G A Herbert; W B Cherry; G C Taylor
Journal:  J Immunol       Date:  1967-06       Impact factor: 5.422

8.  Gut mucosa barrier preservation by orally administered IgA-IgG to patients undergoing bone marrow transplantation: a randomised pilot study.

Authors:  J E Johansson; T Ekman
Journal:  Bone Marrow Transplant       Date:  1999-07       Impact factor: 5.483

9.  Metadata matters: access to image data in the real world.

Authors:  Melissa Linkert; Curtis T Rueden; Chris Allan; Jean-Marie Burel; Will Moore; Andrew Patterson; Brian Loranger; Josh Moore; Carlos Neves; Donald Macdonald; Aleksandra Tarkowska; Caitlin Sticco; Emma Hill; Mike Rossner; Kevin W Eliceiri; Jason R Swedlow
Journal:  J Cell Biol       Date:  2010-05-31       Impact factor: 10.539

Review 10.  Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors:  Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal:  AAPS J       Date:  2009-11-19       Impact factor: 4.009

View more
  10 in total

1.  Antibody-mediated depletion of viral reservoirs is limited in SIV-infected macaques treated early with antiretroviral therapy.

Authors:  Adrienne E Swanstrom; Taina T Immonen; Kelli Oswald; Cathi Pyle; James A Thomas; William J Bosche; Lorna Silipino; Michael Hull; Laura Newman; Vicky Coalter; Adam Wiles; Rodney Wiles; Jacob Kiser; David R Morcock; Rebecca Shoemaker; Randy Fast; Matthew W Breed; Joshua Kramer; Duncan Donohue; Tyler Malys; Christine M Fennessey; Charles M Trubey; Claire Deleage; Jacob D Estes; Jeffrey D Lifson; Brandon F Keele; Gregory Q Del Prete
Journal:  J Clin Invest       Date:  2021-03-15       Impact factor: 14.808

2.  Maternally transferred mAbs protect neonatal mice from HSV-induced mortality and morbidity.

Authors:  Iara M Backes; Brook K Byrd; Matthew D Slein; Chaya D Patel; Sean A Taylor; Callaghan R Garland; Scott W MacDonald; Alejandro B Balazs; Scott C Davis; Margaret E Ackerman; David A Leib
Journal:  J Exp Med       Date:  2022-09-26       Impact factor: 17.579

3.  Recombinant expressing angiopep-2 fused anti-VEGF single chain Fab (scFab) could cross blood-brain barrier and target glioma.

Authors:  Xuemei Ji; Hongyan Wang; Yue Chen; Junfei Zhou; Yu Liu
Journal:  AMB Express       Date:  2019-10-15       Impact factor: 3.298

4.  Non-neutralizing Antibodies May Contribute to Suppression of SIVmac239 Viremia in Indian Rhesus Macaques.

Authors:  Nuria Pedreño-Lopez; Brandon C Rosen; Walter J Flores; Matthew J Gorman; Thomas B Voigt; Michael J Ricciardi; Kristin Crosno; Kim L Weisgrau; Christopher L Parks; Jeffrey D Lifson; Galit Alter; Eva G Rakasz; Diogo M Magnani; Mauricio A Martins; David I Watkins
Journal:  Front Immunol       Date:  2021-03-16       Impact factor: 8.786

5.  Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques.

Authors:  Patrick J Madden; Muhammad S Arif; Mark E Becker; Michael D McRaven; Ann M Carias; Ramon Lorenzo-Redondo; Sixia Xiao; Cecily C Midkiff; Robert V Blair; Elizabeth Lake Potter; Laura Martin-Sancho; Alan Dodson; Elena Martinelli; John-Paul M Todd; Francois J Villinger; Sumit K Chanda; Pyone Pyone Aye; Chad J Roy; Mario Roederer; Mark G Lewis; Ronald S Veazey; Thomas J Hope
Journal:  Front Immunol       Date:  2021-12-24       Impact factor: 7.561

6.  PET/CT targeted tissue sampling reveals virus specific dIgA can alter the distribution and localization of HIV after rectal exposure.

Authors:  Roslyn A Taylor; Sixia Xiao; Ann M Carias; Michael D McRaven; Divya N Thakkar; Mariluz Araínga; Edward J Allen; Kenneth A Rogers; Sidath C Kumarapperuma; Siqi Gong; Angela J Fought; Meegan R Anderson; Yanique Thomas; Jeffrey R Schneider; Beth Goins; Peter Fox; Francois J Villinger; Ruth M Ruprecht; Thomas J Hope
Journal:  PLoS Pathog       Date:  2021-06-01       Impact factor: 7.464

7.  Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues.

Authors:  Ann M Carias; Jeffrey R Schneider; Patrick Madden; Ramon Lorenzo-Redondo; Mariluz Araínga; Amarendra Pegu; Gianguido C Cianci; Danijela Maric; Francois Villinger; John R Mascola; Ronald S Veazey; Thomas J Hope
Journal:  J Immunol       Date:  2021-06-23       Impact factor: 5.426

8.  Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research.

Authors:  M Paximadis; S Perez Patrigeon; R Rajasuriar; R Tatoud; E Scully; P Arbuthnot
Journal:  J Virus Erad       Date:  2019-11-04

Review 9.  Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics.

Authors:  Matthew R Gardner
Journal:  Front Cell Infect Microbiol       Date:  2020-04-23       Impact factor: 5.293

Review 10.  Stepping forward in antibody-drug conjugate development.

Authors:  Yiming Jin; Megan A Schladetsch; Xueting Huang; Marcy J Balunas; Andrew J Wiemer
Journal:  Pharmacol Ther       Date:  2021-06-24       Impact factor: 12.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.